Apontis Pharma AG
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
APPH | F
Overview
Corporate Details
- ISIN(s):
- DE000A3CMGM5 (+1 more)
- LEI:
- 894500ETO1J6MR8PDF91
- Country:
- Germany
- Address:
- Alfred-Nobel-Straße 10, 40789 Monheim am Rhein
- Website:
- https://apontis-pharma.de/en/
- Sector:
- Manufacturing
Description
Apontis Pharma AG is a pharmaceutical company that specializes in the development, marketing, and distribution of 'Single Pills'. These are fixed-dose combination drugs that unite two or three active pharmaceutical ingredients into a single tablet. The company's portfolio primarily focuses on treating cardiovascular diseases and other chronic conditions. By simplifying treatment regimens, the Single Pill approach aims to improve patient adherence and therapy outcomes, offering medical and economic benefits to the healthcare system. Apontis Pharma also engages in co-marketing activities for established pharmaceutical products.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-03-28 07:30 |
APONTIS PHARMA expects profitable growth again in 2024
|
English | 47.3 KB | ||
| 2024-03-28 00:00 |
Jahresabschluss 2023
|
German | 3.5 MB | ||
| 2024-03-28 00:00 |
Annual financial statements 2023
|
English | 3.4 MB | ||
| 2024-02-26 00:00 |
Jahresabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
|
German | 26.6 KB | ||
| 2024-02-06 07:30 |
APONTIS PHARMA successfully completes performance and efficiency improvement pr…
|
English | 13.1 KB | ||
| 2023-11-09 07:30 |
APONTIS PHARMA presents details of the restructuring and efficiency program Ni…
|
English | 44.1 KB | ||
| 2023-11-08 20:00 |
APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring…
|
English | 6.8 KB | ||
| 2023-08-10 07:30 |
APONTIS PHARMA confirms preliminary figures H1 2023 sales and earnings decline
|
English | 40.4 KB | ||
| 2023-08-10 00:00 |
Half-yearly financial statements 2023
|
English | 281.6 KB | ||
| 2023-07-31 18:40 |
APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2…
|
English | 6.9 KB | ||
| 2023-07-27 22:15 |
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term plann…
|
English | 13.7 KB | ||
| 2023-07-27 22:10 |
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term plann…
|
English | 7.0 KB | ||
| 2023-07-10 13:50 |
APONTIS PHARMA: CEO Karlheinz Gast resigns for personal reasons - Bruno Wohlsch…
|
English | 9.7 KB | ||
| 2023-07-10 13:45 |
APONTIS PHARMA AG: CEO Karlheinz Gast resigns from office for personal reasons
|
English | 6.6 KB | ||
| 2023-06-29 07:30 |
APONTIS PHARMA launches Single Pill Finder and distribution of Single Pill Rosa…
|
English | 11.4 KB |
Automate Your Workflow. Get a real-time feed of all Apontis Pharma AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Apontis Pharma AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Apontis Pharma AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-14 | Milz, Thomas | Board | Buy | None | 8,960.00 EUR |
| 2024-05-14 | be executive GmbH | Close relation | Buy | None | 8,880.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 10,128.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 3,396.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 1,692.00 EUR |
| 2024-05-13 | Zimmermann, Thomas | Other | Buy | None | 1,688.00 EUR |
| 2023-05-05 | Reineke, Silke | Close relation | Buy | None | 36,625.00 EUR |
| 2023-05-05 | Milz, Thomas | Board | Buy | None | 14,360.00 EUR |
Peer Companies
